Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice

Journal of Lipid Research

Volumn 49, Issue 3, 2008, Pages 572-580

  Nelbach, Lisa ^a   Shu, Xiao ^a,b   Konrad, Robert J ^c   Ryan, Robert O ^a,b   Forte, Trudy M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Apolipoprotein A V enzyme linked immunosorbent assay; Apolipoprotein A V knockout mouse; Apolipoprotein B 100; Apolipoprotein E; Human apolipoprotein A V transgenic mouse; Nuclear magnetic resonance; Redistribution of apolipoprotein A V

Indexed keywords

APOLIPOPROTEIN A5; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOA5 PROTEIN, HUMAN; APOA5 PROTEIN, MOUSE; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENETIC ENGINEERING; HOMEOSTASIS; HYPERLIPIDEMIA; INCUBATION TIME; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECT; GENETICS; MOUSE MUTANT; PARTICLE SIZE;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; LIPOPROTEINS; LIPOPROTEINS, LDL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PARTICLE SIZE; TRIGLYCERIDES;

EID: 42949117999     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700281-JLR200     Document Type: Article

References (39)

1. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J-C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
2. Schaap, F. G., P. C. N. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. F. M. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
3. Pennacchio, L. A., M. Olivier, J. A. Hubacek, R. M. Krauss, E. M. Rubin, and J. C. Cohen. 2002. Two independent apolipoprotein AV haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11: 3031-3038.
4. Talmud, P. J., E. Hawe, S. Martin, M. Olivier, G. J. Miller, E. M. Rubin, L. A. Pennacchio, and S. E. Humphries. 2002. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11: 3039-3046.
5. Nabika, T., S. Nasreen, S. Kobayashi, and J. Masuda. 2002. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 165: 201-204.
6. Ribalta, J., L. Figuera, J. Fernandez-Ballart, E. Vilella, M. Castro Cabezas, L. Masana, and J. Joven. 2002. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin. Chem. 48: 1597-1600.
7. Oliva, C. P., L. Pisciotta, G. L. Volti, M. P. Sambataro, A. Cantafora, A. Bellocchio, A. Catapano, P. Tarugi, S. Bertolini, and S. Calandra. 2005. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25: 411-417.
8. Marcais, C., B. Verges, S. Charrière, V. Pruneta, M. Merlin, S. Billon, L. Perrot, J. Drai, A. Sassolas, L. A. Pennacchio, et al. 2005. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J. Clin. Invest. 115: 2862-2869.
9. van der Vliet, H. N., M. G. Sammels, A. C. J. Leegwater, J. H. M. Levels, P. H. Reitsma, W. Boers, and R. A. F. M. Chamuleau. 2001. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem. 276: 44512-44520.
10. O'Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51: 351-359.
11. Ishihara, M., T. Kujiraoka, T. Iwasaki, M. Nagano, M. Takano, J. Ishii, M. Tsuji, H. Ide, I. P. Miller, N. E. Miller, et al. 2005. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J. Lipid Res. 46: 2015-2022.
12. Schaap, F. G., M. C. Nierman, J. F. P. Berbée, H. Hattori, P. J. Talmud, S. F. C. Vaessen, P. C. N. Rensen, R. A. F. M. Chamuleau, J. A. Kuivenhoven, and A. K. Groen. 2006. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J. Lipid Res. 47: 2333-2339.
13. Talmud, P. J., J. A. Cooper, H. Hattori, I. P. Miller, G. J. Miller, and S. E. Humphries. 2006. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia. 49: 2337-2340.
14. Dallinga-Thie, G. M., A. van Tol, H. Hattori, L. C. van Vark-van der Zee, H. Jansen, and E. J. G. Sijbrands. 2006. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 49: 1505-1511.
15. Alborn, W. E., M. J. Prince, and R. J. Konrad. 2007. Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes. Clin. Chim. Acta. 378: 154-158.
16. Henneman, P., F. G. Schaap, L. M. Havekes, P. C. N. Rensen, R. R. Frants, A. van Tol, H. Hattori, A. H. M. Smelt, and K. W. van Dijk. 2007. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 193: 129-134.
17. Vaessen, S. F. C., F. G. Schaap, J-A. Kuivenhoven, A. K. Groen, B. A. Hutten, S. M. Boekholdt, H. Hattori, M. S. Sandhu, S. A. Bingham, R. Luben, et al. 2006. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J. Lipid Res. 47: 2064-2070.
18. Merkel, M., B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren. 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280: 21553-21560.
19. Lookene, A., J. A. Beckstead, S. Nilsson, G. Olivecrona, and R. O. Ryan. 2005. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280: 25383-25387.
20. Beckstead, J. A., M. N. Oda, D. D. O. Martin, T. M. Forte, J. K. Bielicki, T. Berger, R. Luty, C. M. Kay, and R. O. Ryan. 2003. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry. 42: 9416-9423.
21. Lindgren, F. T., L. C. Jensen, and F. T. Hatch. 1972. The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. G. J. Nelson, editor. Wiley-Interscience, New York. 181-274.
22. Otvos, J. D. 2002. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab. (Zaragoza). 48: 171-180.
23. Freedman, D. S., J. D. Otvos, E. J. Jeyarajah, I. Shalaurova, L. A. Cupples, H. Parise, R. B. D'Agostino, P. W. Wilson, and E. J. Schaefer. 2004. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin. Chem. 50: 1189-1200.
24. Festa, A., K. Williams, A. J. G. Hanley, J. D. Otvos, D. C. Goff, L. E. Wagenknecht, and S. M. Haffner. 2005. Nuclear magnetic resonance (NMR) lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 111: 3465-3472.
25. Markwell, M. A. K., S. M. Haas, N. E. Tolbert, and L. L. Bieber. 1981. Protein determination in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol. 72: 296-303.
26. Abramoff, M. D., P. J. Magelhaes, and S. J. Ram. 2004. Image processing with Image J. Biophotonics International. 11: 36-42.
27. Rasband, W. S. 1997-2006. Image J. National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/.
28. Wang, Y., K. Tran, and Z. Yao. 1999. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells: a unified model for the assembly of very low density lipoproteins. J. Biol. Chem. 274: 27793-27800.
29. Grosskopf, I., N. Baroukh, S. J. Lee, Y. Kamari, D. Harats, E. M. Rubin, L. A. Pennacchio, and A. D. Cooper. 2005. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 25: 2573-2579.
30. Fruchart-Najib, J., E. Baugé, L-S. Niculescu, T. Pham, B. Thomas, C. Rommens, Z. Majd, B. Brewer, L. A. Pennacchio, and J-C. Fruchart. 2004. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319: 397-404.
31. Linton, M. F., J. B. Atkinson, and S. Fazio. 1995. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation. Science. 267: 1034-1037.
32. Boisvert, W. A., J. Spangenberg, and L. K. Curtiss. 1995. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J. Clin. Invest. 96: 1118-1124.
33. Hasty, A. H., M. F. Linton, L. L. Swift, and S. Fazio. 1999. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J. Lipid Res. 40: 1529-1538.
34. Nilsson, S. K., A. Lookene, J. A. Beckstead, J. Gliemann, R. O. Ryan, and G. Olivecrona. 2007. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry. 46: 3896-3904.
35. Dichlberger, A., L. A. Cogburn, J. Nimpf, and W. J. Schneider. 2007. Avian apolipoprotein A-V binds to LDL receptor gene family members. J. Lipid Res. 48: 1451-1456.
36. Shu, X., J. Chan, R. O. Ryan, and T. M. Forte. 2007. Apolipoprotein A-V association with intracellular lipid droplets. J. Lipid Res. 48: 1445-1450.
37. Weinberg, R. B., V. R. Cook, J. A. Beckstead, D. D. O. Martin, J. W. Gallagher, G. S. Shelness, and R. O. Ryan. 2003. Structure and interfacial properties of human apolipoprotein A-V. J. Biol. Chem. 278: 34438-34444.
38. Beckstead, J. A., K. Wong, V. Gupta, C-P. L. Wan, V. R. Cook, R. B. Weinberg, P. M. M. Weers, and R. O. Ryan. 2007. The C terminus of apolipoprotein A-V modulates lipid-binding activity. J. Biol. Chem. 282: 15484-15489.
39. vander Vliet, H. N., F. G. Schaap, J. H. M. Levels, R. Ottenhoff, N. Looije, J. G. Wesseling, A. K. Groen, and R. A. F. M. Chamuleau. 2002. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295: 1156-1159.